search
Back to results

The Effects of Dexmedetomidine and Remifentanil on Carotid Patients

Primary Purpose

Carotid Artery Stenosis

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Remifentanil
Dexmedetomidine
Sponsored by
The Cleveland Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Carotid Artery Stenosis focused on measuring Carotid Endarterectomy patients

Eligibility Criteria

50 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Consenting adult patients (age >50 years) undergoing carotid endarterectomy with general anesthesia. Exclusion Criteria: Receiving another alpha 2-adrenoreceptor agonist; Contraindication to dexmedetomidine, including allergy; Current hepatic disease (liver function tests > twice upper limit of normal); Renal insufficiency, as defined by a creatinine > 2.0 mg/dL; Mentally impairment, including dementia or delirium; Heart block ; Sick sinus syndrome; Atrial fibrillation with a low ventricular response (< 50 bpm); Absolute or relative hypovolemia; Prior stroke; Severe left-ventricular dysfunction

Sites / Locations

  • Cleveland Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Remifentanil

Dexmedetomidine

Arm Description

Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical

Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.

Outcomes

Primary Outcome Measures

Mean Arterial Pressure
Visual Analogue Scale (VAS) Pain Score
Using a ruler, the score is determined by measuring the distance on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-10. 0 = no pain and 10 = worst
Intravenous Morphine Equivalents During Post-anesthesia Care Unit (PACU) After Surgery
intravenous morphine equivalents (mg)

Secondary Outcome Measures

Full Information

First Posted
June 8, 2006
Last Updated
August 9, 2017
Sponsor
The Cleveland Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT00335972
Brief Title
The Effects of Dexmedetomidine and Remifentanil on Carotid Patients
Official Title
Phase 4: The Effects of Dexmedetomidine and Remifentanil on Postoperative Hemodynamics and Pain/Opioids in Patients Undergoing Carotid Endarterectomy
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Terminated
Why Stopped
Closed due to lack of enrollment
Study Start Date
June 2006 (undefined)
Primary Completion Date
May 2008 (Actual)
Study Completion Date
May 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Cleveland Clinic

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
We propose to test whether intraoperative administration of dexmedetomidine will reduce hemodynamic control in the intra- and post-operative periods and reduces PACU analgesic requirements in patients undergoing carotid endarterectomy.
Detailed Description
Remifentanil is an amidopiperidine derivative with unique pharmacokinetic properties. Its steady-state volume of distribution is 30 L (3). Its context-sensitive half life is consistently short (3.2 min), even after prolonged infusion(4). The pharmacokinetic profile of remifentanil is independent of the hepatic (5) and renal function (6). And finally, the recovery profile of remifentanil is excellent with a speedy anesthetic emergence time which is important for a quick and proper neurologic assessment in the early postoperative period. Remifentanil produces good intraoperative hemodynamic control during intense noxious stimulation like laryngoscopy, endotracheal intubation, and during pinning of the head (8). However, side effects of remifentanil include hypotension and bradycardia (15) intraoperatively, along with apnea(16,17) and hyperalgesia(18) postoperatively which is caused by increasing sensitivity to noxious stimuli. Investigations demonstrate different mechanisms of opioid-induced post-infusion anti-analgesia and secondary hyperalgesia (9). Overall remifentanil is a versatile opioid that is being increasingly used in the operating room. DEXMEDETOMIDINE (DEX), an alpha-2 adrenoreceptor agonist, is gaining popularity in neuroanesthesia. It has a desirable neurophysiologic profile including neuroprotective characteristics through its effect on α2A receptor subtypes (10). Its hypnotic effect is mediated through the α2 receptors in the locus ceruleus and its analgesic properties are mediated through an effect on the dorsal horn of the spinal cord (11,12). Since it has sympatholytic and antinociceptive properties, it may improve hemodynamic stability at critical moments of neurosurgical stimulation. Dexmedetomidine reduces anesthetic drug and opioid requirements in the perioperative period (13,14). In addition, dexmedetomidine does not affect evoked potential monitoring, (19) making it a favorable anesthetic adjunct in cases in which neurophysiologic monitoring is being used. In recent years, dexmedetomidine has emerged as an effective drug useful in a wide range of anesthesia related areas. Study Questions We postulate that dexmedetomidine provides better hemodynamic control in the intra- and post-operative periods and reduces PACU analgesic requirements. Primary Hypothesis 1: Intraoperative dexmedetomidine provides better postoperative analgesia than remifentanil, thus reducing PACU opioid requirements. Primary Hypothesis 2: Dexmedetomidine causes fewer hemodynamic perturbations than remifentanil.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carotid Artery Stenosis
Keywords
Carotid Endarterectomy patients

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
142 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Remifentanil
Arm Type
Active Comparator
Arm Description
Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
Arm Title
Dexmedetomidine
Arm Type
Active Comparator
Arm Description
Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
Intervention Type
Drug
Intervention Name(s)
Remifentanil
Intervention Description
Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Intervention Description
Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
Primary Outcome Measure Information:
Title
Mean Arterial Pressure
Time Frame
mean arterial pressure at 15, 30, 45, 60, and 90 minutes after extubation
Title
Visual Analogue Scale (VAS) Pain Score
Description
Using a ruler, the score is determined by measuring the distance on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-10. 0 = no pain and 10 = worst
Time Frame
pain score measured at 15, 30, 45, 60, and 90 minutes after extubation
Title
Intravenous Morphine Equivalents During Post-anesthesia Care Unit (PACU) After Surgery
Description
intravenous morphine equivalents (mg)
Time Frame
During Post-anesthesia care unit after surgery,an average of 4 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Consenting adult patients (age >50 years) undergoing carotid endarterectomy with general anesthesia. Exclusion Criteria: Receiving another alpha 2-adrenoreceptor agonist; Contraindication to dexmedetomidine, including allergy; Current hepatic disease (liver function tests > twice upper limit of normal); Renal insufficiency, as defined by a creatinine > 2.0 mg/dL; Mentally impairment, including dementia or delirium; Heart block ; Sick sinus syndrome; Atrial fibrillation with a low ventricular response (< 50 bpm); Absolute or relative hypovolemia; Prior stroke; Severe left-ventricular dysfunction
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ehab Farag, MD
Organizational Affiliation
The Cleveland Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Effects of Dexmedetomidine and Remifentanil on Carotid Patients

We'll reach out to this number within 24 hrs